Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Copeland

Showing results (111-120 of 125) with videos related to

Pageof 13
Sort By:
Kidney Medicine|November 13, 2024
Living Donor Candidates' Self-reported Health and Health Perceptions and Completion of Donor Evaluation: A Cohort StudyElaine Ku, Sabrina Legaspi, Timothy P Copeland, et al.
Ecology|December 9, 2009
Wolverine gene flow across a narrow climatic nicheMichael K Schwartz, Jeffrey P Copeland, Neil J Anderson, et al.
Journal of Inherited Metabolic Disease|March 26, 2010
Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapyJohn Marshall, Kerry Anne McEachern, Wei-Lien Chuang, et al.
Plos One|December 3, 2010
Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry diseaseJohn Marshall, Karen M Ashe, Dinesh Bangari, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 15, 2018
Geographic Variation in Postoperative Imaging for Low-Risk Breast CancerBenjamin L Franc, Timothy P Copeland, Robert Thombley, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 18, 2024
Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD TrialsElaine Ku, Timothy P Copeland, Charles E McCulloch, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 19, 2025
Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney DiseaseKristen L Nowak, Timothy P Copeland, Elaine Ku, et al.
Molecular Genetics and Metabolism|May 19, 2007
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher diseaseKerry Anne McEachern, John Fung, Svetlana Komarnitsky, et al.
NPJ Breast Cancer|August 23, 2018
Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosisShih-Ying Huang, Benjamin L Franc, Roy J Harnish, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 11, 2026
Renal blood flow and progression to kidney failure in ADPKDKristen L Nowak, Timothy P Copeland, Elaine Ku, et al.
Pageof 13

Showing results (111-120 of 125) with videos related to

Sort By:
Pageof 13
Kidney Medicine|November 13, 2024
Living Donor Candidates' Self-reported Health and Health Perceptions and Completion of Donor Evaluation: A Cohort StudyElaine Ku, Sabrina Legaspi, Timothy P Copeland, et al.
Ecology|December 9, 2009
Wolverine gene flow across a narrow climatic nicheMichael K Schwartz, Jeffrey P Copeland, Neil J Anderson, et al.
Journal of Inherited Metabolic Disease|March 26, 2010
Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapyJohn Marshall, Kerry Anne McEachern, Wei-Lien Chuang, et al.
Plos One|December 3, 2010
Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry diseaseJohn Marshall, Karen M Ashe, Dinesh Bangari, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 15, 2018
Geographic Variation in Postoperative Imaging for Low-Risk Breast CancerBenjamin L Franc, Timothy P Copeland, Robert Thombley, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 18, 2024
Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD TrialsElaine Ku, Timothy P Copeland, Charles E McCulloch, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 19, 2025
Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney DiseaseKristen L Nowak, Timothy P Copeland, Elaine Ku, et al.
Molecular Genetics and Metabolism|May 19, 2007
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher diseaseKerry Anne McEachern, John Fung, Svetlana Komarnitsky, et al.
NPJ Breast Cancer|August 23, 2018
Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosisShih-Ying Huang, Benjamin L Franc, Roy J Harnish, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 11, 2026
Renal blood flow and progression to kidney failure in ADPKDKristen L Nowak, Timothy P Copeland, Elaine Ku, et al.
Pageof 13